JTC Employer Solutions Trustee Ltd Sells 243 Shares of Becton, Dickinson and Company (NYSE:BDX)

JTC Employer Solutions Trustee Ltd lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 30.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 560 shares of the medical instruments supplier’s stock after selling 243 shares during the quarter. JTC Employer Solutions Trustee Ltd’s holdings in Becton, Dickinson and Company were worth $127,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Sound Income Strategies LLC boosted its position in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the period. Central Pacific Bank Trust Division boosted its position in Becton, Dickinson and Company by 22.5% during the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 45 shares during the period. Tompkins Financial Corp boosted its position in Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares during the period. Birch Capital Management LLC boosted its position in Becton, Dickinson and Company by 0.4% during the third quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier’s stock worth $2,838,000 after purchasing an additional 48 shares during the period. Finally, Radnor Capital Management LLC boosted its position in Becton, Dickinson and Company by 1.7% during the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock worth $708,000 after purchasing an additional 48 shares during the period. Institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the transaction, the executive vice president now directly owns 24,345 shares in the company, valued at $5,380,488.45. This trade represents a 15.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Shana Carol Neal sold 788 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the transaction, the executive vice president now owns 16,201 shares in the company, valued at $3,807,235. The trade was a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,747 shares of company stock valued at $1,949,520 over the last three months. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock traded up $2.11 on Monday, reaching $235.78. The stock had a trading volume of 663,170 shares, compared to its average volume of 1,718,234. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $248.42. The company has a market cap of $68.38 billion, a P/E ratio of 39.69, a price-to-earnings-growth ratio of 1.64 and a beta of 0.39. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average is $226.91 and its two-hundred day moving average is $232.45.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. Becton, Dickinson and Company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the firm posted $3.42 earnings per share. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 9th were paid a $1.04 dividend. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a yield of 1.76%. The ex-dividend date was Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 70.03%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BDX. Evercore ISI increased their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $283.50.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.